8-K
filed April 7, 2023, 7:59 PM ET
CIK 0001832415
other material
confidence high
sentiment negative
materiality 0.81
Better Therapeutics, Inc.: Nasdaq/NYSE listing notice — BTTX raises $6.5M at $0.825/share; receives Nasdaq deficiency notice
Better Therapeutics, Inc.
- Private placement of 7.88M shares (~$6.5M gross) at $0.825/share, with officer/director participation; closes ~April 10.
- Loan amendment with Hercules halts amortization payments until Aug 1 (or Nov 1 if benchmarks met) and waives prepayment penalty.
- Nasdaq notified company of stockholders' deficit ($899k) below $2.5M min; must submit compliance plan by May 19, 2023.
- Proceeds plus expense reductions expected to extend runway through potential FDA decision on BT-001.
Key facts
Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
Better Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- stockholders equity
- Rules
- 5550(b)(1)
Exact text from the filing
of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Annual Report on Form 10-K for the year ended December 31, 2022, reported stockholders’ deficit of $899,000, which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. The Letter further noted that as of its date, the Company did not have a
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Better Therapeutics, Inc. amended First Amendment to Loan Agreement with Hercules Capital, Inc. (effective 2023-04-05).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc.
- Effective
- 2023-04-05
Exact text from the filing
On April 5, 2023, the Company entered into a First Amendment to Loan Agreement (the “Amendment”) with Hercules Capital, Inc. (the “Administrative Agent”) and the lenders party thereto (the “Lenders”), amending that certain Loan and Security Agreement (the “Loan Agreement”), dated as of August 18, 2021, by and among the Company, the Administrative Agent and the Lenders.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Better Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $6.5 million (effective 2023-04-06).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors
- Value
- approximately $6.5 million
- Effective
- 2023-04-06
Exact text from the filing
On April 6, 2023, Better Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”) providing for the private placement (the “Private Placement”) to the Purchasers of an aggregate of 7,878,786 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), for an aggregate purchase price of approximately $6.5 million (or $0.825 per Share).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.